BioNet-Asia Organized International Pertussis Symposium Celebrating its 15th Anniversary in Bangkok

Information Technology Press Releases Friday April 21, 2017 17:02
Bangkok--21 Apr--BioNet-Asia

BioNet-Asia Co. Ltd organized the first International Symposium on Advances in Pertussis Immunisation in Bangkok, Thailand. The Symposium was attended by more than 300 international and Thai experts on pertussis vaccination as well as public health stakeholders, involving expert presentations and session chairing by world leaders on pertussis immunization including Prof. Stanley Plotkin (USA), Dr. Nicole Guiso (France), Prof. Terry Nolan (Australia), Prof. Keith Klugman (USA) and prominent public health leaders from Thailand including Prof. Teerapong Tantawichien and Prof. Tawee Chotpitayasundondh. The symposium coincided with BioNet's 15th Anniversary, and the recent Marketing Approval of two of its new recombinant pertussis booster vaccines.

In his keynote presentation, Emeritus Prof. Stanley Plotkin (University of Pennsylvania, USA) discussed the reappearance of pertussis disease (whooping cough) in countries around the world and the need for new vaccine strategies and new vaccines to address this global problem. "The availability of a monovalent acellular pertussis vaccine could provide the medical community with a new way to approach pertussis immunization, especially in adolescents and pregnant women to protect their newborns" said Prof Plotkin. Western countries like Australia and USA that have been using acellular pertussis vaccines in their immunization programs since the late 90's, have turned to recommending repeated pertussis booster vaccinations throughout life to control the spread of pertussis disease in their countries. "The protection induced by pertussis vaccines and infection is short-lived, so by keeping vaccine coverage high and revaccinating different age groups, France manages to decrease the incidence of the less than 6 months of age since 1996 ", Dr Nicole Guiso said, explaining why France still observes cycles of the disease but their intensity seems lower that those seen in other European countries. While it is mainly western countries that are reporting a rise in pertussis disease, the pertussis situation in low- and middle income countries (using whole cell pertussis vaccines) is largely unknown. "What we need are data from countries with a high uptake of whole-cell pertussis and this requires reliable surveillance systems to detect the burden of pertussis in neonatal deaths", said Prof Keith Klugman, Director of Pneumonia at the Bill and Melinda Gates Foundation.

The Symposium was a perfect moment for BioNet to share data with the audience on two of its new pertussis vaccines, PertagenTM and BoostagenTM, produced using recombinant DNA technology, for which BioNet received Marketing Authorization Approval (MAA) from the Thai Food and Drug Administration for active booster immunization against pertussis in individuals from the age of 11 years onwards late December 2016. In her presentation Director of Clinical Development Dr. Simonetta Viviani (BioNet, Thailand) showed that in a Phase II/III clinical trial BioNet's pertussis booster vaccines induced higher antibody responses compared to one of the currently available vaccines. "Other studies evaluating PertagenTM are planned in other countries. For example, a Phase II study is currently underway in Switzerland", BioNet's CEO Pham Hong Thai announced. Emeritus Prof. Piyasakol Sakolsatayadam, Minister of Public Health, Thailand, congratulated BioNet on this achievement: "I am very proud that a Thai company is making such a significant contribution to the pertussis world agenda".

About BioNet-Asia

BioNet-Asia offers access to vaccine and technology through biotech innovation and partnering networks. BioNet has built several international partnerships fostering vaccine self-reliance and leading to the supply of billions of doses of vaccines worldwide. BioNet has also a broad pipeline of vaccines in R&D and clinical stages. BioNet-Asia's pertussis vaccine is produced from a new proprietary Bordetella pertussis strain expressing genetically detoxified Pertussis Toxin (PTgen). The unique properties of BioNet PTgen enable the vaccine to induce superior anti-PT immune response. BioNet-Asia successfully demonstrated in a Phase II/III trial that its acellular pertussis vaccine (containing PTgen and FHA), as a monovalent or in combination, could significantly boost immunity against pertussis in adolescents and adults. For additional information, please visit www.bionet-asia.com.

BioNet Contact
Laurent Dapremont, Director Strategic Business Development, BioNet-Asia Co. Ltd.
+66 (2) 361 8110
laurent.d@bionet-asia.com
www.bionet-asia.com

Latest Press Release

Huawei Inks MoU with DE Ministry To Accelerate Digital Transformation Thailand#s Eastern Economic Corridor Chosen as Location for Its Leading-edge Cloud Data Center in Southeast Asia

Today, the Thai Ministry of Digital Economy and Society and Huawei Thailand signed a Memorandum of Understanding (MoU) on "Public-Private Collaboration on Digital Transformation to Move Thailand 4.0 Forward", with the aim to extend further cooperation in...

Commercial Aviation leads the way in leveraging digital transformation Augmented reality identified as key technology to mitigate aircraft downtime

IFS, the global enterprise applications company, today announced the commercial aviation industry-specific results of its Digital Change Survey. The study found that the aviation sector is more advanced in leveraging digital transformation than the other...

Huawei Helps China Insurance Giant CPIC Leads in the Digital Era

"For traditional financial services companies, digitalization is neither a label nor a trend, but a key factor that is crucial to the long-time survival of an enterprise. The CPIC digital strategy aims to innovate business models by leveraging technical...

iPhone X arrives at AIS on November, 24, 2017

AIS today announced it will offer iPhone X, the future of the smartphone, featuring a revolutionary new design with a stunning all-screen display. Customers will be able to pre-order iPhone X beginning November, 17, 2017 at www.ais.co.th/iPhoneX and it...

3D at Your Fingertips - Wacom unveils the Pro Pen 3D for intuitive creating, sculpting and designing

Today Wacom announced the Wacom Pro Pen 3D, a digital pen equipped with new features empowering professional designers and artists to bring their best work to life. Designed for use on a Wacom MobileStudio Pro, Cintiq Pro or the 2017 Intuos Pro pen...

Related Topics